GLP Watchdog
Invyncible logo

Invyncible Review

Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 6.7/10

Best for: compounded tirzepatide at $210/month

6.7
★★★☆☆3.4/5

Invyncible falls below our bar on medical oversight. Read the breakdown below before you give it money.

$192.5/mo

Covered by the monthly price

Medication

Not stated

Clinician visits

Not stated

Shipping

Not stated

Lab work

Not stated

Coaching

Not stated

See plans →

No insurance neededVetted by our editors

Compare top-rated alternatives ↓

Invyncible does not publish its pricing tiers; they surface only after the sign-up flow. The Florida-based platform sells semaglutide and tirzepatide programs for weight management, openly discloses its corporate parent and physical address where competitors hide ownership behind a trade name, and displays a LegitScript verification seal. There is no long-term commitment.

By Ruth Calder · Enforcement Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
GLP-1 from $210/moPrice after intake40 statesNo FDA letter on record

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

Vetted alternatives to Invyncible

7.9/ 10
Verified partner

Oak

Best for: semaglutide at $119/month, 37% under the register median

★★★★☆4/5

Editorial score · methodology

$119/mo
CompoundedSemaglutideTirzepatideGlutathioneNAD+LegitScript Verified
Get StartedRead full Oak review →
6.5/ 10
Verified partner

Direct Meds

Best for: compounded semaglutide at $249/month

★★★☆☆3.3/5

Editorial score · methodology

$249/mo
CompoundedSemaglutideTirzepatideNAD+SermorelinLegitScript VerifiedFDA Warning
Get StartedRead full Direct Meds review →
8.8/ 10
Verified partner

Found

Best for: tirzepatide at $169/month, 37% under the register median

★★★★☆4.4/5

Editorial score · methodology

$99/mo
CompoundedSemaglutideTirzepatideOrforglipron
Get StartedRead full Found review →
Invyncible logo
3.4 / 5
Our editorial rating
Visit Invyncible →

from $192.5/mo · no insurance needed

Invyncible at a glance

Type
GLP-1 telehealth provider
Medications
Semaglutide, Tirzepatide
Starting price
$192.5/mo (Listed at $192.50 against a $275.00 list price. Programs are sold per vial with an approximate duration, not as a cal...)
Availability
40 states
FDA status
No FDA warning letter on record

How Invyncible scores

Six columns, each one computed from something Invyncible has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.

Value25%

6.7/10

$210/month is 21% below the register median of $267 for compounded tirzepatide.

Effectiveness25%

10.0/10

Dispenses semaglutide and tirzepatide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).

User Experience15%

3.0/10

On the seller's own pages, no price appears until the medical intake is finished.

Trust & Safety15%

5.0/10

does not name a dispensing pharmacy; withholds price until after the intake; publishes its state list. Our verification confidence is medium.

Accessibility10%

8.4/10

Publishes coverage in 40 of 50 states.

Support10%

5.0/10

States too little about what the monthly cost covers to score the bundle. Held at the midpoint rather than assumed.

6weighted dimensions
560sellers in the register
Everychecked against the seller's own site
Value 25%Effectiveness 25%User Experience 15%Trust & Safety 15%Accessibility 10%Support 10%

A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →

What we checked on Invyncible

Last checked July 2026
  • Re-read the price on file across 2 dose or plan tiers
  • Checked state coverage: 40 states
  • Searched our FDA enforcement register for this operator

Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: medium.

What signing up with Invyncible involves

Assembled from this seller’s entry in the register — the price record, the state list, the dispensing pharmacy where one is named, and what the monthly figure covers. It describes what a reader can expect to meet on the way to a prescription, and what is missing from the seller’s own disclosures. It is not a clinical judgment and not a prescribing decision.

  1. 1Invyncible does not show a price until you have worked through its medical questionnaire. Budget for the fact that you cannot compare it against anything until you have handed over health information.
  2. 2The intake is a written questionnaire. No live video visit or baseline bloodwork is recorded as required.
  3. 3Invyncible does not say which pharmacy dispenses the medication. That is common here and it means you cannot check the pharmacy's record before you buy.
Price shown only after intake
  • Cheapest standing monthly prices on record: tirzepatide $210. Membership fees, first-month rates and insured copays are excluded from those figures.
  • Coverage is published for 40 of 50 states.
  • The medication is compounded, so it is not an FDA-approved product and has not been reviewed by the agency for safety, effectiveness or manufacturing quality.

Invyncible support, as documented

Phone
855-862-9510
Hours
Monday–Friday, 9am–5pm EST

GLP-1 medications Invyncible offers

Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.

SemaglutideTirzepatideWegovyOzempicMounjaroZepboundRybelsus

Peptides Invyncible offers

Invyncible sells peptides beyond the GLP-1s. Tap one to read what the evidence says about it.

DropletGlutathioneAntioxidant infusionsDropletNAD+Energy & cellular agingSyringeSermorelinOwn growth-hormone output

Pricing

Prices re-verified

Semaglutide Injections Program — starter vial (~0.5 mg weekly, 2.5 mg vial, roughly 5 weeks)Compounded
$192.5/mo
semaglutide

Listed at $192.50 against a $275.00 list price. Programs are sold per vial with an approximate duration, not as a calendar month — see the review notes.

Tirzepatide Injection Program — standard formulaCompounded
$210/mo
tirzepatide

Listed at $210.00 against a $300.00 list price. Cheaper combination formulas exist: tirzepatide/glycine/B12 $180.00 and semaglutide/glycine/B12 $149.00.

Check the price yourself before you pay

Every figure here was read off Invyncible's own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.

See Invyncible pricing →

In its favor

  • Tirzepatide at $210 a month, within the normal band around this register's $267 median for the same drug and form
  • Coverage is published for 40 states
  • No FDA warning letter matched this operator when we searched our enforcement register

Against it

  • No price appears until the medical intake is complete, so the cost cannot be compared before health information is submitted
  • No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
  • Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality

What Invyncible charges

The standing price at Invyncible is $192.5/month.

  • Compounded semaglutide — $192.5/month
  • Compounded tirzepatide — $210/month

The median across the GLP-1 providers we track is about $169/month, so this lands mid-market — close enough that the deciding factor is unlikely to be price.

Found dispenses semaglutide and tirzepatide from $149/month, which makes it the honest comparison to run before committing here.

What Invyncible dispenses

Invyncible prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the pair carrying the strongest published outcome data. These are compounded preparations from a licensed pharmacy rather than approved pens, which is where the lower price comes from. A compounded drug is not FDA-approved as a finished product — the specific preparation has not been reviewed for safety, efficacy or manufacturing quality.

What we could verify

On the record: it operates in 40 states. We searched the federal warning-letter record for this operator and came back with nothing. Because the medication is compounded and no dispensing pharmacy is named publicly, the single most useful question to ask at intake is which licensed pharmacy fills the prescription. A seller that will not answer that has told you something. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.

Who should look elsewhere

  • You want the FDA-approved pen specifically. Nothing here is the approved finished product.
  • You need to bill insurance. Like most of this market, this is cash-pay.

Our read

Invyncible lands mid-market on price without a standout advantage or an obvious problem. It comes down to whether its particular package fits. Breeze Meds is the nearest comparison we track, and worth reading alongside this.

The Bottom Line

Invyncible falls below our bar on medical oversight. Read the breakdown below before you give it money.

Score: 6.7/10Best for: compounded tirzepatide at $210/monthFrom: $192.5/mo

Before you pay Invyncible

Starting at $192.5/month. Check today's price, then book the free consultation.

Visit Invyncible →

Where Invyncible is the wrong choice

No seller in this register suits every reader, and saying otherwise would be the easiest way to sell one. On these four counts another entry does better.

  • If you need the FDA-approved pen rather than a compounded vial, consider Found.
  • If the standing monthly cost is what decides it, consider Telos Rx (from $99/mo).
  • If you want a human checking in, not just a prescription, consider Oak.
See all alternatives to Invyncible →

Frequently Asked Questions

Glossary

The words sellers use, defined. Tap any term.

Sources

Cited across this Invyncible review: primary regulatory filings, and peer-reviewed studies.

Sources & methodology — as of August 2026
  1. 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
  2. 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  3. 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
  4. 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
  5. 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
  6. 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
  7. 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  8. 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
  9. 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
  10. 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  11. 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
  12. 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.

See Invyncible's current pricing

Plans start at $192.5/month. The free consultation is where you learn whether you qualify, and what it costs today.

Visit Invyncible →